New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
18:49 EDTHUSA, OCLR, HTZ, PPHM, URBN, MLNK, CYSOn The Fly: After Hours Movers
HIGHER: Urban Outfitters (URBN), up 7% after the company's 10-Q filing outlined expansion plans, positive Q4 SSS... Oclaro (OCLR), up 3% after announcing preliminary merger litigation settlement... CYS Investments (CYS), up 2% after announcing 52c per share special dividend... DOWN AFTER EARNINGS: Peregrine Pharmaceuticals (PPHM), down 3%... ALSO LOWER: Houston American Energy (HUSA), down 53% after abandoning the Zorro Gris #1 well... ModusLink (MLNK), down 5% after announcing it would delay the filing of its 10-Q... Hertz Global (HTZ), down 3% after announcing the sale of 50M shares of common stock by holders.
News For URBN;OCLR;CYS;PPHM;HUSA;MLNK;HTZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 2, 2015
13:34 EDTHTZRyanair to pursue Hertz for breach of contract
Subscribe for More Information
12:23 EDTHTZHertz ends partnership with Ryanair
Hertz (HTZ) said that it has ended its car hire agreement with Ryanair (RYAAY). Hertz said that existing bookings will be fully honored and that future bookings can be made directly at the Hertz, Thrifty and Firefly websites.
July 1, 2015
17:16 EDTMLNKModusLink, SP Corporate extend management services agreement
Subscribe for More Information
June 26, 2015
11:46 EDTHTZHertz in exclusive negotiations with Loxam for potential HERC acquisition
Subscribe for More Information
June 25, 2015
16:23 EDTHTZOn The Fly: Top stock stories for Thursday
Subscribe for More Information
11:35 EDTHTZAvis, Hertz slide after Credit Suisse notes pricing challenges
Subscribe for More Information
08:40 EDTPPHMPeregrine granted keu EU patent for bavituximab
Peregrine Pharmaceuticals announced that the European Patent Office, or EPO, has granted Patent Number 2,269,656, titled "Selected Antibodies Binding to Aminophospholipids and their Use in Treatment, Such as Cancer”. This important patent covers bavituximab as a composition of matter and for use in treating cancer including in combination with radiotherapy or chemotherapy, such as with docetaxel. The new patent covers bavituximab as a composition of matter, a range of related antibodies, including humanized and chain-shuffled antibodies and other sequence variations and their broad use in any diagnosis or therapy. The new patent also covers antibody drug conjugates, diagnostic and imaging constructs, liposomal and pharmaceutical combinations of bavituximab and related antibodies.
05:50 EDTHTZStocks with implied volatility movement; HTZ XLF
Subscribe for More Information
June 23, 2015
09:18 EDTHTZHertz's subsidiary HERC names Bruce Dressel as COO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use